China-based biotech Innogen is making a strategic pivot toward international visibility following regulatory clearance of its ...

Boston, USA-based biotech Antares Therapeutics, launched yesterday with $177 million in Series A financing. Antares is a spin ...

Belgian drugmaker UCB (Euronext: UCB) today announced new three-year data from Phase III trials, and their open-label ...

Spanish biotech SpliceBio has secured $135 million in series B financing to accelerate development of its experimental gene ...

Gilead Sciences has paused five clinical trials of its investigational HIV drugs GS-1720 and GS-4182 after the American medicines regulator raised safety concerns. The once-weekly oral regimen was ...

A fresh attempt to bring more pharmaceutical manufacturing back to US soil has put the sector on alert, as a new executive ...

Last month, the Future Health Report was presented at the World Health Assembly in Geneva, Switzerland. The report states ...

Oxford, UK-based biotech SynaptixBio, which is developing a therapy for a rare, deadly, and currently incurable rare disease ...

UK privately-held T-regulatory (Treg) cell therapies developer Quell Therapeutics today revealed that pharma major ...

New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, closed Monday’s trading nearly ...

UK-based microbiome company Microbiotica has appointed Robert Tansley its chief medical officer (CMO).

Privately-owned German biotech XL-protein GmbH today announced that it has entered into a worldwide license, development and ...